

Keegan Mitchell  
 Form 3  
 September 04, 2009

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Keegan Mitchell		(Month/Day/Year)	CURIS INC [CRIS]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
45 MOULTON STREET			(Check all applicable)	
(Street)			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below)    (specify below) Vice-President	
CAMBRIDGE,Â MAÂ 02138			6. Individual or Joint/Group Filing(Check Applicable Line)	
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable    Expiration Date	Title    Amount or Number of Shares			

Edgar Filing: Keegan Mitchell - Form 3

Qualified stock option (right to buy)	Â (1)	05/16/2018	Common Stock	150,000	\$ 1.35	D	Â
Qualified stock option (right to buy)	Â (2)	10/24/2018	Common Stock	18,750	\$ 0.79	D	Â
Qualified stock option (right to buy)	Â (3)	02/05/2019	Common Stock	27,500	\$ 1.07	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Keegan Mitchell 45 MOULTON STREET CAMBRIDGE, MA 02138	Â	Â	Â Vice-President	Â

## Signatures

Michael P. Gray,  
attorney-in-fact

09/04/2009

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Options vest over a period of four years with 25% of the stock options vesting the first anniversary of the grant date, or May 16, 2009, and an additional 6.25% of the shares during each successive three-month period thereafter until the option is fully vested on the fourth anniversary of the grant date, or May 16, 2012, subject to continued employment. All stock options will expire 10 years from date of grant and the grant date for each option is 10 years prior to the expiration date. 103,125 of these options remain unvested as of September 2, 2009.

(2) Common stock subject to stock option award shall become exercisable on April 24, 2014 or upon the consummation of a collaboration, licensing or other similar agreement regarding the Targeted Cancer Drug Development Platform that includes an up-front cash payment of at least \$10 million. For clarity, the cash payment shall be attributable to a nonrefundable license fee or other similar payment and shall not include an equity investment in Curis and any vesting is subject to continued service with the Curis.

(3) Options vest over a period of four years with 25% of the stock options vesting the first anniversary of the grant date, or February 5, 2010, and an additional 6.25% of the shares during each successive three-month period thereafter until the option is fully vested on the fourth anniversary of the grant date, or February 5, 2013, subject to continued employment. All stock options will expire 10 years from date of grant and the grant date for each option is 10 years prior to the expiration date. All of these options remain unvested as of September 2, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.